AADi’s first product, ABI-009, nanoparticle albumin-bound sirolimus (rapamycin), a highly active form of sirolimus complexed with albumin, is based on the same technology as Abraxane® (nab-paclitaxel, Abraxis Bioscience, acquired by Celgene Corp in 2010 for ~$3B, 2015 sales $967M). The albumin-bound platform technology was invented and developed by Dr. Desai and colleagues at Abraxis.
ABI-009 is a clinical phase, targeted mTOR inhibitor with demonstrated safety and evidence of efficacy in a Phase I trial in patients with solid tumors. ABI-009 has a markedly different pharmacological and pharmacokinetic profile compared to any other mTOR inhibitor. Unlike other mTOR inhibitors, ABI-009 is being developed in highly select populations in diseases driven by mTOR activations. ABI-009 is licensed to AADi by Celgene for Oncology, Cardiovascular and metabolic related diseases.
Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010;9(4):963-975.
Gasper WJ, Jimenez CA, Walker J, Conte MS, Seward K, Owens CD. Adventitial Nab-Rapamycin Injection Reduces Porcine Femoral Artery Luminal Stenosis Induced by Balloon Angioplasty via Inhibition of Medial Proliferation and Adventitial Inflammation. Circ Cardiovasc Interv. 2013.
Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, et al. Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clin Cancer Res. 2013;19(19):5474-5484.
